Extensive research
Aiforia: Promisingly started growth journey is just beginning
Aiforia has gained a promising first foothold in the clinical segment of digital pathology. We continue to see the company in a good competitive position and on a clear trajectory to grow into one of the long-term winners in its market. On the other hand, poor growth predictability and elevated financing risks argue for some caution in pricing the company's potential. However, at the current share price, we believe that the company's value creation potential outweighs the risks.
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.
Read more on company pageKey Estimate Figures28.02.2024
| 2022 | 23e | 24e | |
|---|---|---|---|
| Revenue | 1.6 | 2.5 | 4.5 |
| growth-% | 64.9 % | 56.2 % | 79.2 % |
| EBIT (adj.) | -11.8 | -12.6 | -11.2 |
| EBIT-% (adj.) | -731.9 % | -502.9 % | -248.7 % |
| EPS (adj.) | -0.47 | -0.50 | -0.43 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
